Table S2.
Medication by region for those on systemic treatment for first line only (n=316)
| Region
|
||||||
|---|---|---|---|---|---|---|
| US (n=159) (%) |
UK (n=34) (%) |
Spain (n=32) (%) |
Italy (n=35) (%) |
Germany (n=24) (%) |
France (n=32) (%) |
|
| Cytotoxic chemotherapies | ||||||
| Doxorubicin | 12.6 | 52.9 | 28.1 | 40.0 | 45.8 | 43.8 |
| Cisplatin | 5.0 | 14.7 | 21.9 | 40.0 | 8.3 | 12.5 |
| Docetaxel | 6.3 | 8.8 | 3.1 | 5.7 | 0.0 | 9.4 |
| Paclitaxel | 7.5 | 2.9 | 6.2 | 25.7 | 4.2 | 15.6 |
| Etoposide | 1.9 | 2.9 | 6.2 | 0.0 | 4.2 | 0.0 |
| Other chemotherapy drugs | 0.6 | 0.0 | 0.0 | 14.3 | 4.2 | 9.4 |
| MKIs | ||||||
| Sorafenib | 44.7 | 26.5 | 43.8 | 20.0 | 25.0 | 34.4 |
| Sunitinib | 22.0 | 8.8 | 25.0 | 8.6 | 12.5 | 12.5 |
| Vandetanib | 18.2 | 2.9 | 0.0 | 5.7 | 4.2 | 6.2 |
| Cabozantinib | 5.7 | 0.0 | 0.0 | 5.7 | 4.2 | 0.01 |
| Pazopanib | 5.7 | 2.9 | 0.0 | 0.0 | 4.2 | 6.2 |
| Axitinib | 2.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other MKIs | 1.9 | 2.9 | 9.4 | 0.0 | 0.0 | 0.0 |
Abbreviation: MKI, multikinase inhibitor.